About Be Pharmaceuticals Private Limited
Data last updated: 20 December 2025
Be Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Biological E Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 29 August 2011, the company has been in operation for over 15 years.
Registered with ROC Hyderabad under CIN U24100MH2011PTC221406.
Capital: an authorised share capital of ₹6 Cr and a paid-up capital of ₹5.01 Cr. Formerly known as Akorn India Private Limited. It is led by directors including Rudaraju Anand Kumar and Mahipal Reddy Saddi.
Last AGM: 18 September 2024. Financial statements filed for year ended 31 March 2024. Office: 18/1 & 3 Azamabad, Hyderabad, Telangana, India – 500020.
As per the financials filed for FY 2025, the company reported a revenue of ₹67.68 Lakh, a decline of 12% compared to the previous year.
The company has a workforce of approximately 3 employees as per the latest available data. It operates as a subsidiary of Biological E Limited.
The company is associated with 1 brand - Akorn India. As per MCA filings, the company has satisfied charges of ₹20 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website akornindia.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered Address18/1 & 3 Azamabad, Hyderabad, Telangana, India – 500020
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Be Pharmaceuticals Private Limited
Be Pharmaceuticals Private Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is U24100TG2011PTC148362, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24100TG2011PTC148362 | Current |
| U24100MH2011PTC221406 | Previous |
| U24100DL2011PTC262196 | Previous |
Associated Brands with Be Pharmaceuticals Private Limited
Be Pharmaceuticals Private Limited operates one associated brand: Akorn India. These brands represent Be Pharmaceuticals Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Sterile pharmaceuticals are developed, manufactured, and marketed by Akorn India. | akornindia.com |
Competitors & Alternatives of Be Pharmaceuticals Private Limited
Brands and companies operating in the same space as Be Pharmaceuticals Private Limited include Exela Pharma, Gland Pharma, Luoxin Pharmaceutical Group and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Exela Pharma
|
Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | Lenoir, United States, United States | 2005 |
Gland Pharma
|
Generic injectable drugs are manufactured across therapeutic segments. | Hyderabad, India, India | 1978 |
Luoxin Pharmaceutical Group
|
Developer and manufacturer of pharmaceutical products | Linyi, China, China | 2006 |
Summit Biosciences
|
Nasal spray drug products are developed, manufactured, and commercialized. | Lexington, United States, United States | 2008 |
August Bioservices
|
Diversified research services for clinical solutions are offered. | Nashville, United States, United States | 2017 |
ApiJect
|
Medicine injectors are manufactured by ApiJect for medical applications. | Stamford, United States, United States | 2015 |
Vetter Pharma
|
CDMO specializing in aseptically prefilled syringe systems, cartridges and vials. | Ravensburg, Germany, Germany | 1950 |
INCOG BioPharma Services
|
Injectable drug products are manufactured by this biopharma CDMO. | United States | 2020 |
Nitin Lifesciences
|
CMO of small volume parenteral injectables | Karnal, India, India | 1994 |
Business Activity of Be Pharmaceuticals Private Limited
Be Pharmaceuticals Private Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Board of Directors of Be Pharmaceuticals Private Limited
Be Pharmaceuticals Private Limited is currently managed by 3 directors, with 16 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Rudaraju Anand Kumar
Also directs:
Biological E. Limited, Biotech Medicals Private Limited, Lacto-Cosmetics (Hyd) Pvt Ltd and 5 more
|
Director | 14 Aug 2020 | 5 Years 10 Months | Current |
| Mahipal Reddy Saddi | Director | 26 Aug 2020 | 5 Years 10 Months | Current |
| Mahima Datla | Director | 14 Aug 2020 | 5 Years 10 Months | Current |
Financials of Be Pharmaceuticals Private Limited FY 2024 filings available
Be Pharmaceuticals Private Limited reported revenue of ₹67.68 Lakh (down 12% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings of Be Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Jul 2014 | Icici Bank Limited | ₹20 Cr | Satisfied |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Be Pharmaceuticals Private Limited
View historical data on people associated with Be Pharmaceuticals Private Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Be Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Be Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Be Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Be Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Be Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Be Pharmaceuticals Private Limited
MSME Payment Delays by Be Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Be Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Be Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Be Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Be Pharmaceuticals Private Limited
MCA Filings & Documents of Be Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Be Pharmaceuticals Private Limited
Recent News on Be Pharmaceuticals Private Limited
Frequently Asked Questions about Be Pharmaceuticals Private Limited
Be Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 29 August 2011 (15+ years old) and is registered under CIN U24100TG2011PTC148362. The company has 3 employees.
Be Pharmaceuticals Private Limited reported revenue of ₹67.68 Lakh for FY 2025 (down 12.00% YoY).
The current directors of Be Pharmaceuticals Private Limited are:
The primary industry of Be Pharmaceuticals Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Be Pharmaceuticals Private Limited can be reached at the registered office: 181 & 3 Azamabad, Hyderabad, Telangana, India – 500020, or through the website akornindia.com.
The authorised capital is ₹6 Cr, and the paid-up capital is ₹5.01 Cr.